Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
US-9220244-B2 · Dec 29, 2015 · US
US9963502B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9963502-B2 |
| Application number | US-201615230928-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 8, 2016 |
| Priority date | Feb 19, 2009 |
| Publication date | May 8, 2018 |
| Grant date | May 8, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to an antibody which specifically binds to unprocessed and/or partially processed neurotoxin polypeptide or an antibody which specifically binds an epitope consisting of a peptide having an amino acid sequence as shown in any one of SEQ ID NOs: 1 to 16 and to methods for the manufacture of such antibodies. Moreover, the present invention relates to a composition comprising processed neurotoxin polypeptide free of unprocessed or partially processed neurotoxin polypeptide and a method for manufacturing said neurotoxin polypeptide based on the antibodies of the invention. The present invention also relates to the use of the aforementioned antibody for separating processed neurotoxin polypeptides from unprocessed or partially processed neurotoxin polypeptides or for determining unprocessed or partially processed neurotoxin polypeptides. The present invention relates to a method for the manufacture of a medicament.
Opening claim text (preview).
The invention claimed is: 1. An antibody coupled to a solid support, which antibody specifically binds an epitope, wherein the epitope is a peptide consisting of the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15 or SEQ ID NO: 16, and wherein the antibody specifically binds partially processed or unprocessed Clostridium neurotoxin polypeptides and does not cross react with completely processed Clostridium neurotoxin polypeptides. 2. The antibody of claim 1 , which is a monoclonal or polyclonal antibody.
Ophthalmic agents · CPC title
Antiepileptics; Anticonvulsants · CPC title
for peripheral neuropathies · CPC title
Clostridium (G) · CPC title
with the first amino acid being basic · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.